OncohematologyOncohematologyОнкогематология1818-83462413-4023Publishing House ABV Press11410.17650/1818-8346-2014-9-2-45-52HEMATOPOIETIC STEM CELL TRANSPLANTATIONТРАНСПЛАНТАЦИЯ ГЕМОПОЭТИЧЕСКИХ СТВОЛОВЫХ КЛЕТОК У ПАЦИЕНТОВ С ГЕМОБЛАСТОЗАМИRisk factors of CMV replication after allogeneic hematopoietic stem cell transplantation in children and adolescentsФакторы риска реактивации цитомегаловирусной инфекции у детей и подростков после различных видов аллогенной трансплантации гемопоэтических стволовых клетокShiriaevS. N.ШиряевС. Н.
Russian Federation
ftk9@yandex.ruStanchevaN. V.СтанчеваН. В.
Russian Federation
MorozovaYe. V.МорозоваЕ. В.
Russian Federation
BarkhatovI. M.БархатовИ. М.
Russian Federation
AverianovaM. Yu.АверьяноваМ. Ю.
Russian Federation
RazumovaS. V.РазумоваС. В.
Russian Federation
GoloshchapovO. V.ГолощаповО. В.
Russian Federation
ChukhlovinA. B.ЧухловинА. Б.
Russian Federation
ZubarovskayaL. S.ЗубаровскаяЛ. С.
Russian Federation
AfanasievB. V.АфанасьевБ. В.
Russian Federation
Raisa Gorbacheva Memorial Institute of Children Oncology, Hematology and Transplantation, I. P. Pavlov First Saint Petersburg State Medical University, Ministry of Health of RussiaНИИ детской онкологии, гематологии и трансплантологии им. Р. М. Горбачевой ГБОУ ВПО Первый СПбГМУ им. акад. И. П. Павлова Минздрава России170920149245521709201417092014https://oncohematology.abvpress.ru/ongm/article/view/114

Risk factors of CMV replication in early period after allo-HSCT (D0‑D100) were – myeloablative conditioning – HR 3.74 (1.67–8.37), р = 0.001; unrelated donor – HR 2.18 (0.86–5.26), р = 0.10; HLA-matched donor – HR 0.24 (0.05–1.06), р = 0,06. In late posttransplant period (from D+100) significant risk factors of CMV-reactivation were (according to multivariate analysis) myeloablative conditioning – HR 13.17 (3.00–57.86), р = 0.001; combination of pretransplant remission of leukemia and using cyclosporine and methotrexate – HR 0.13 (0.03–0.50), р = 0.003; combination of aGVHD and CMV reactivation in early posttransplant period – HR 2.71 (0.86–8.50), р = 0.088; using of bone marrow – HR 0.37 (0.12–1.19), р = 0.095. We revealed the significant association of aGVHD and CMV-reactivation –OR 2.91 (1.07–7.92), р=0.006, and increased rate of cGVHD in patients with CMV replication at third month after allo-HSCT OR – 2.29 (1.03–5.08), р = 0.066. We revealed a tend to decreasing relapse risk in patients who had CMV-replication – HR 0.07 (0.004–1.17), р = 0.06. Cumulative incidence of CMV-disease was 28 %. CMV-disease was lethal in 44 % patients.

acute lymphoblastic leukemiaacute myeloblastic leukemiacytomegalovirusallogeneic hematopoietic stem cell transplantationострый лимфобластный лейкозострый миелобластный лейкозцитомегаловирусаллогенная трансплантация гемопоэтических стволовых клеток1. Афанасьев Б. В., Зубаровская Л. С., Семенова Е. В. и др. Опыт применения неродственной аллогенной трансплантации стволовых гемопоэтических клеток в клинике трансплантации костного мозга СПбГМУ им. акад. И. П. Павлова. Тер архив 2007;7:36–43.Афанасьев Б. В., Зубаровская Л. С., Семенова Е. В. и др. Опыт применения неродственной аллогенной трансплантации стволовых гемопоэтических клеток в клинике трансплантации костного мозга СПбГМУ им. акад. И. П. Павлова. Тер архив 2007;7:36–43.2. Афанасьев Б. В., Вавилов В. Н., Цандер А. Р. Восстановление лимфоцитов периферической крови у пациентов с гематологическими заболеваниями после аллогенной неродственной трансплантации гемопоэтических стволовых клеток. Тер архив 2007;7:44–7.Афанасьев Б. В., Вавилов В. Н., Цандер А. Р. Восстановление лимфоцитов периферической крови у пациентов с гематологическими заболеваниями после аллогенной неродственной трансплантации гемопоэтических стволовых клеток. Тер архив 2007;7:44–7.3. Семенова Е. В., Станчева Н. В., Паина О. В. и др. Трансплантация костного мозга при остром лимфобластном лейкозе у детей. Сб. мат. I Евразийского конгресса «Трансплантация стволовых клеток». Минск: Профессиональные издания, 2013. С. 159–161.Семенова Е. В., Станчева Н. В., Паина О. В. и др. Трансплантация костного мозга при остром лимфобластном лейкозе у детей. Сб. мат. I Евразийского конгресса «Трансплантация стволовых клеток». Минск: Профессиональные издания, 2013. С. 159–161.4. Бондаренко С. Н., Семенова Е. В., Вавилов В. Н. и др. Аллогенная трансплантация гемопоэтических стволовых клеток при остром миелобластном лейкозе в первой ремиссии. Тер архив 2013;7:18–25.Бондаренко С. Н., Семенова Е. В., Вавилов В. Н. и др. Аллогенная трансплантация гемопоэтических стволовых клеток при остром миелобластном лейкозе в первой ремиссии. Тер архив 2013;7:18–25.5. Румянцев А. Г., Масчан А. А. Трансплантация гемопоэтических стволовых клеток у детей. М.: Медицинское информационное агентство, 2003. 443 с.Румянцев А. Г., Масчан А. А. Трансплантация гемопоэтических стволовых клеток у детей. М.: Медицинское информационное агентство, 2003. 443 с.6. Слесарчук О. А., Бабенко Е. В., Семенова Е. В. и др. Эффективность инфузии донорских лимфоцитов у пациентов после различных видов аллогенной трансплантации гемопоэтических стволовых клеток. Тер архив 2013;85(7):26–33.Слесарчук О. А., Бабенко Е. В., Семенова Е. В. и др. Эффективность инфузии донорских лимфоцитов у пациентов после различных видов аллогенной трансплантации гемопоэтических стволовых клеток. Тер архив 2013;85(7):26–33.7. Балашов Д. Н., Трахтман П. Е., Скоробогатова Е. В. и др. Факторы риска цитомегаловирусной инфекции у пациентов после аллогенной трансплантации гемопоэтических стволовых клеток. Онкогематол 2010;4:20–6.Балашов Д. Н., Трахтман П. Е., Скоробогатова Е. В. и др. Факторы риска цитомегаловирусной инфекции у пациентов после аллогенной трансплантации гемопоэтических стволовых клеток. Онкогематол 2010;4:20–6.8. Nakamae H., Katharine A. K., Sandmaier B. M. et al. Effect of conditioning regimen intensity on CMV infection in allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant 2009;15(6):694–703.Nakamae H., Katharine A. K., Sandmaier B. M. et al. Effect of conditioning regimen intensity on CMV infection in allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant 2009;15(6):694–703.9. Morecki S., Gelfand Y., Nagler A. et al. Immune reconstitution following allogeneic stem cell transplantation in recipients onditioned by low intensity vs myeloablative regimen. Bone Marrow Transplant 2001;28(3):243–9.Morecki S., Gelfand Y., Nagler A. et al. Immune reconstitution following allogeneic stem cell transplantation in recipients onditioned by low intensity vs myeloablative regimen. Bone Marrow Transplant 2001;28(3):243–9.10. Perez-Simon J. A., Kottaridis P. D., Martino R. et al. Nonmyeloablative transplantation with or withoutPerez-Simon J. A., Kottaridis P. D., Martino R. et al. Nonmyeloablative transplantation with or withoutalemtuzumab: comparison between 2 prospective studies in patients with lymphoproliferative disorders. Blood 2002;100:3121–7.11. Oh S. J., Lee K. H., Lee J. H. et al. The risk of cytomegalovirus infection in nonmyeloablative peripheral stem cell transplantation compared with conventional bone marrow transplantation. J Korean Med Sci 2004;19:172–6.Oh S. J., Lee K. H., Lee J. H. et al. The risk of cytomegalovirus infection in nonmyeloablative peripheral stem cell transplantation compared with conventional bone marrow transplantation. J Korean Med Sci 2004;19:172–6.12. Mohty M., Mohty A. M., Blaise D. et al. Cytomegalovirus-specific immune recovery following allogeneic HLA-identical sibling transplantation with reduced-intensity preparative regimen. Bone Marrow Transplant 2004;33;839–46.Mohty M., Mohty A. M., Blaise D. et al. Cytomegalovirus-specific immune recovery following allogeneic HLA-identical sibling transplantation with reduced-intensity preparative regimen. Bone Marrow Transplant 2004;33;839–46.13. Kalpoe J. S., van der Heiden P. L., Vaessen N. et al. Comparable incidence and severity of cytomegalovirus infections following T cell-depleted allogeneic stem cell transplantation preceded by reduced intensity or myeloablative conditioning. Bone Marrow Transplant 2007;40:137–43.Kalpoe J. S., van der Heiden P. L., Vaessen N. et al. Comparable incidence and severity of cytomegalovirus infections following T cell-depleted allogeneic stem cell transplantation preceded by reduced intensity or myeloablative conditioning. Bone Marrow Transplant 2007;40:137–43.14. Hill Q. A., Hill A., Collyns T. A. et al. Similar lymphocyte recovery and CMV reactivation profiles between reduced intensity conditioning with alemtuzumab and myeloablative allogeneic stem cell transplantation. Bone Marrow Transplant 2008;41:749–51.Hill Q. A., Hill A., Collyns T. A. et al. Similar lymphocyte recovery and CMV reactivation profiles between reduced intensity conditioning with alemtuzumab and myeloablative allogeneic stem cell transplantation. Bone Marrow Transplant 2008;41:749–51.15. Nachbaur D., Larcher C., Kircher B. et al. Risk for cytomegalovirus infection following reduced intensity allogeneic stem cell transplantation. Ann Hematol 2003;82:621–7.Nachbaur D., Larcher C., Kircher B. et al. Risk for cytomegalovirus infection following reduced intensity allogeneic stem cell transplantation. Ann Hematol 2003;82:621–7.16. Shi-Xia X., Hai-Qin X., Xian-Hua T. et al. Comparison of reduced intensity and myeloablative conditioning regimens for stem cell transplantation in patients with malignancies: a meta-analysis. Clin Transplant 2011;25(2):E187–98.Shi-Xia X., Hai-Qin X., Xian-Hua T. et al. Comparison of reduced intensity and myeloablative conditioning regimens for stem cell transplantation in patients with malignancies: a meta-analysis. Clin Transplant 2011;25(2):E187–98.17. Patel S. R., Ridwan R. U., Ortin M. Cytomegalovirus reactivation in pediatric hemopoietic progenitors transplant: a retrospective study on the risk factors and the efficacy of treatment. J Pediatr Hematol Oncol 2005;27:411–5.Patel S. R., Ridwan R. U., Ortin M. Cytomegalovirus reactivation in pediatric hemopoietic progenitors transplant: a retrospective study on the risk factors and the efficacy of treatment. J Pediatr Hematol Oncol 2005;27:411–5.18. Schetelig J., Oswald O., Steuer N. et al. Cytomegalovirus infections in allogeneic stem cell recipients after reduced-intensity or myeloablative conditioning assessed by quantitative PCR and p65‑antigenemia. Bone Marrow Transplant 2003;32:695–701.Schetelig J., Oswald O., Steuer N. et al. Cytomegalovirus infections in allogeneic stem cell recipients after reduced-intensity or myeloablative conditioning assessed by quantitative PCR and p65‑antigenemia. Bone Marrow Transplant 2003;32:695–701.19. Cantoni N., Hirsch M., Khanna N. et al. Evidence for a bidirectional relationship between cytomegalovirus replication and acute graft-versus-host disease. Biol Blood Marrow Transplant 2010;16:1309–14.Cantoni N., Hirsch M., Khanna N. et al. Evidence for a bidirectional relationship between cytomegalovirus replication and acute graft-versus-host disease. Biol Blood Marrow Transplant 2010;16:1309–14.20. Ljungman P., de la Camara R., Einsele H. et al. Recommendations for CMV and HHV-6 management in patient with hematological diseases. 4th European Conference on infections in leukemia, 2011.Ljungman P., de la Camara R., Einsele H. et al. Recommendations for CMV and HHV-6 management in patient with hematological diseases. 4th European Conference on infections in leukemia, 2011.21. Behrendt C. E., Rosenthal J., Bolotin E. et al. Donor and recipient CMV serostatus and outcome of pediatric allogeneic HSCT for acute leukemia in the era of CMVpreemptive therapy. Biol Blood Marrow Transplant 2009;15:54–60.Behrendt C. E., Rosenthal J., Bolotin E. et al. Donor and recipient CMV serostatus and outcome of pediatric allogeneic HSCT for acute leukemia in the era of CMVpreemptive therapy. Biol Blood Marrow Transplant 2009;15:54–60.22. Einsele H., Hebart H., Kauffmann-Schneider C. et al. Risk factors for treatment failures in patients receiving PCR-based preemptive therapy for CMV infection. Bone Marrow Transplant 2000;25:757–63.Einsele H., Hebart H., Kauffmann-Schneider C. et al. Risk factors for treatment failures in patients receiving PCR-based preemptive therapy for CMV infection. Bone Marrow Transplant 2000;25:757–63.23. Zaia J. A., Schmidt G. M., Chao N. J. et al. Preemptive ganciclovir administration based solely on asymptomatic pulmonary cytomegalovirus infection in allogeneic – recipients: long-term follow-up. Biol Blood Marrow Transplant 1995;1:88–93.Zaia J. A., Schmidt G. M., Chao N. J. et al. Preemptive ganciclovir administration based solely on asymptomatic pulmonary cytomegalovirus infection in allogeneic – recipients: long-term follow-up. Biol Blood Marrow Transplant 1995;1:88–93.24. Söderberg-Nauclér C., Fish K. N., Nelson J. A. et al. Reactivation of latent human cytomegalovirus by allogeneic stimulation of blood cells from healthy donors. Cell 1997;91:119.Söderberg-Nauclér C., Fish K. N., Nelson J. A. et al. Reactivation of latent human cytomegalovirus by allogeneic stimulation of blood cells from healthy donors. Cell 1997;91:119.25. Söderberg-Nauclér C., Streblow D. N., Fish K. N. et al. Reactivation of latent human cytomegalovirus in CD14+ monocytes is differentiation dependent. J Virol 2001;75(16):7543–54.Söderberg-Nauclér C., Streblow D. N., Fish K. N. et al. Reactivation of latent human cytomegalovirus in CD14+ monocytes is differentiation dependent. J Virol 2001;75(16):7543–54.26. Hambach L., Stadler M., Dammann E. et al. Increased risk of complicated CMV infection with the use of mycophenolate mofetil in allogeneic stem cell transplantation. Bone Marrow Transplant 2002;29; 903–6.Hambach L., Stadler M., Dammann E. et al. Increased risk of complicated CMV infection with the use of mycophenolate mofetil in allogeneic stem cell transplantation. Bone Marrow Transplant 2002;29; 903–6.27. George B., Kerridge I., Gilroy N. et al. Fludarabine-based reduced intensity conditioning transplants have a higher incidence of cytomegalovirus reactivation compared with myeloablative transplants. Bone Marrow Transplant 2010;45;849–55.George B., Kerridge I., Gilroy N. et al. Fludarabine-based reduced intensity conditioning transplants have a higher incidence of cytomegalovirus reactivation compared with myeloablative transplants. Bone Marrow Transplant 2010;45;849–55.28. Zhuravskaya T., Maciejewski J. P., Netski D. M. et al. Spread of human cytomegalovirus (HCMV) after infection of human hematopoietic progenitor cells: model of HCMV latency. Blood 1997;90(6):2482–91.Zhuravskaya T., Maciejewski J. P., Netski D. M. et al. Spread of human cytomegalovirus (HCMV) after infection of human hematopoietic progenitor cells: model of HCMV latency. Blood 1997;90(6):2482–91.29. Reddy V., Meier-Kriesche H. U., Greene S. et al. Increased levels of tumor necrosis factor alpha are associated with an increased risk of cytomegalovirus infection after allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 2005;11(9):698–705.Reddy V., Meier-Kriesche H. U., Greene S. et al. Increased levels of tumor necrosis factor alpha are associated with an increased risk of cytomegalovirus infection after allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 2005;11(9):698–705.30. Ljungman P., Perez-Bercoff L., Jonsson J. et al. Risk factors for the development of cytomegalovirus disease after allogeneic stem cell transplantation. Haematologica 2006;91:78–83.Ljungman P., Perez-Bercoff L., Jonsson J. et al. Risk factors for the development of cytomegalovirus disease after allogeneic stem cell transplantation. Haematologica 2006;91:78–83.31. Pinana J. L., Martino R., Barba P. et al. Cytomegalovirus infection and disease after reduced intensity conditioning allogeneic stem cell transplantation: single-centre experience. Bone Marrow Transplant 2010;45;534–42.Pinana J. L., Martino R., Barba P. et al. Cytomegalovirus infection and disease after reduced intensity conditioning allogeneic stem cell transplantation: single-centre experience. Bone Marrow Transplant 2010;45;534–42.32. Junghanss C., Boeckh M., Carter R. A. et al. Incidence and outcome of cytomegalovirus infections following nonmyeloablative compared with myeloablative allogeneic stem cell transplantation, a matched control study. Blood 2002;99:1978–85.Junghanss C., Boeckh M., Carter R. A. et al. Incidence and outcome of cytomegalovirus infections following nonmyeloablative compared with myeloablative allogeneic stem cell transplantation, a matched control study. Blood 2002;99:1978–85.33. Paulin T., Ringden O., Nilsson B. et al. Variables predicting bacterial and fungal infections after allogeneic marrow engraftment. Transplantation 1987;43:393–8.Paulin T., Ringden O., Nilsson B. et al. Variables predicting bacterial and fungal infections after allogeneic marrow engraftment. Transplantation 1987;43:393–8.34. Аверьянова М. Ю., Вавилов В. Н., Бондаренко С. Н. и др. Бактериальные инфекции у пациентов детского и подросткового возраста после трансплантации аллогенных гемопоэтических стволовых клеток: этиология, структура, факторы риска. Журн инфектологии 2013;5(1):35–43.Аверьянова М. Ю., Вавилов В. Н., Бондаренко С. Н. и др. Бактериальные инфекции у пациентов детского и подросткового возраста после трансплантации аллогенных гемопоэтических стволовых клеток: этиология, структура, факторы риска. Журн инфектологии 2013;5(1):35–43.35. Larsson K., Aschan J., Remberger M. et al. Reduced risk for extensive chronic graft-versus-host disease in patients receiving transplants with human leukocyte antigen-identical sibling donors given polymerase chain reaction-based preemptive therapy against cytomegalovirus. Transplantation 2004;77(4):526–31.Larsson K., Aschan J., Remberger M. et al. Reduced risk for extensive chronic graft-versus-host disease in patients receiving transplants with human leukocyte antigen-identical sibling donors given polymerase chain reaction-based preemptive therapy against cytomegalovirus. Transplantation 2004;77(4):526–31.36. Fletcher J. M., Prentice H. G., Grundy J. E. Natural killer cell lysis of cytomegalovirus (CMV) – infected cells correlates with virally induced changes in cell surface lymphocyte function-associated antigen-3 (LFA-3) expression and not with the CMV-induced down-regulation of cell surface class I HLA. J Immunol 1998;161(5):2365–74.Fletcher J. M., Prentice H. G., Grundy J. E. Natural killer cell lysis of cytomegalovirus (CMV) – infected cells correlates with virally induced changes in cell surface lymphocyte function-associated antigen-3 (LFA-3) expression and not with the CMV-induced down-regulation of cell surface class I HLA. J Immunol 1998;161(5):2365–74.37. Erard V., Guthrie K. A., Riddell S., Boeckh M. Impact of HLA A2 and cytomegalovirus serostatus on outcomes in patients with leukemia following matched- sibling myeloablative allogeneic hematopoietic cell transplantation. Haematologica 2006;91(10):1377–83.Erard V., Guthrie K. A., Riddell S., Boeckh M. Impact of HLA A2 and cytomegalovirus serostatus on outcomes in patients with leukemia following matched- sibling myeloablative allogeneic hematopoietic cell transplantation. Haematologica 2006;91(10):1377–83.